Monitoring Patients on Myelofibrosis Treatment
Faculty discuss the best strategies to monitor patients who are receiving treatment of MF as well as commenting on when it might be appropriate to switch therapies.
Read More
Treating Patients with Myelofibrosis and Anemia
Expert oncologists provide insights into how they might manage patients who present with anemia and myelofibrosis in their practice.
Read More
Myelofibrosis: FDA Approved Treatment Options and Updates from ASH 2023
Overview of the current FDA approved treatment options for the management of myelofibrosis as well as reviewing recent updates from ASH 2023 on the SIMPLIFY and PERSIST trials.
Read More
Polycythemia Vera: Choosing the Right Treatment
Panel experts talk about when to use cytoreductive therapy and which factors influence their treatment selection as well as reviewing how patients with PV are monitored.
Read More
Polycythemia Vera: Treatment Goals and Options
Faculty discuss the treatment goals for patients diagnosed with polycythemia vera and review treatment options for managing PV.
Read More
Polycythemia Vera: Assessing Risk and Genetic Testing
Experts discuss the optimal strategy for NGS testing, which alterations to test for and how to assess for risk when diagnosing and managing patients with polycythemia vera (PV).
Read More
KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis
September 26th 2023The hematologic neoplasm systemic mastocytosis is marked by the clonal proliferation of mast cells in the skin, bone marrow, gastrointestinal tract, spleen, and/or liver, caused by an activating KIT mutation in the KIT gene.
Read More
Dr Bose on the Use of Zilurgisertib With/Without Ruxolitinib to Reduce Anemia in Myelofibrosis
June 15th 2023Prithviraj Bose, MD, discusses key data on the use of zilurgisertib alone or in combination with ruxolitinib to reduce disease-related anemia in patients with primary or secondary myelofibrosis.
Read More
Dr. Bose on the Management of Patients With Myelofibrosis Who Progress on Ruxolitinib
June 8th 2020Prithviraj Bose, MD, associate professor in the Department of Leukemia of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses management strategies for patients with myelofibrosis who progress on ruxolitinib (Jakafi).
Read More